This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
41
Unnamed facility
Chandler, Arizona, United States
Unnamed facility
Garden Grove, California, United States
Unnamed facility
Inglewood, California, United States
Summary of Change From Baseline Average Intraocular Pressure Diurnal Measurement by Treatment Group Population (Cohort 1)
Average intraocular pressure (IOP) diurnal measurement is calculated by taking the average of the intraocular pressure measurements at 8AM, 10AM and 4PM. The protocol was later amended (Amendment 09) to a safety only study so the diurnal measurements were no longer collected for Cohorts 2 and 3; only the 8AM IOP was collected as a safety assessment only.
Time frame: Baseline and Day 25
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Redding, California, United States
Unnamed facility
Morrow, Georgia, United States
Unnamed facility
Indianapolis, Indiana, United States
Unnamed facility
Chesterfield, Missouri, United States
Unnamed facility
Kansas City, Missouri, United States
Unnamed facility
Cincinnati, Ohio, United States
Unnamed facility
Portland, Oregon, United States
...and 4 more locations